Across TCGA pan-cancer cohorts, MSRB1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MSRB1 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher MSRB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSRB1 expression acts as an unfavorable survival marker.
KICH are the cancer types where MSRB1 Mutation most reproducibly stratifies survival.